ME/CFS Science @mecfsscience.org · 11/07/20251) The pilot results (n = 10) for the Daratumumab trial on ME/CFS have been published and they look quite encouraging. Tolerability and feasibility were good and some patients had substantial improvements. 1217
ME/CFS Science @mecfsscience.org · 11/07/20252) This comes from the Norwegian team that conducted the Rituximab trials. Both are monoclonal antibodies that target markers on the surface of certain cells. Rituximab targets CD20 which is mainly found on B cells, while Daratumumab targets CD38 found on plasma cells. 170
ME/CFS Science @mecfsscience.org · 11/07/20253) The authors speculate that after an infection, long-lived plasma cells are producing antibodies in ME/CFS. Since these plasma cells are CD20 negative, they are not affected by (short-term) Ritxumab treatment. Hence the idea to try Daratumumab which does target these cells. 170
